AtCor Medical Holdings Limited (AtCor Medical), a developer and marketer of products for cardiovascular disease, has signed two new contracts to supply SphygmoCor systems and clinical trial support services to international pharmaceutical companies. These contracts are with existing clients and have a minimum value of $635,000 and $200,000 respectively. They bring the total value of US pharmaceutical trial contracts secured over the past 10 months to $7.3 million.

Duncan Ross, AtCor Medical chief executive officer, said “These contracts from existing customers to support new clinical trials demonstrate the importance of non-invasive central blood pressure data in drug development, as well as the high quality of the services we provide.”

“Scientific literature shows how important it is to measure central blood pressure in clinical trials and in patient care,” Ross continued. “The recently published Anglo Cardiff II study showed that many patients with controlled brachial blood pressure may have central pressure equivalent to patients with Stage One Hypertension. Many major independent studies, such as CAFE and Strong Heart, have shown that elevated central pressure is a superior predictor of cardiovascular events and that central blood pressure cannot be determined with brachial blood pressure measurements. So, to understand existing cardiovascular risk in subjects enrolled in trials, and the risks and benefits of drugs in development, central blood pressures must be measured.”